Special Issue

Editorial Board Members' Collection Series: Progress and Challenges of Gene Delivery Systems

Message from the Guest Editors

In the last few decades, nucleic acid-based therapy has achieved rapid development leading to the approval of some gene therapeutics. However, the instability, short half-life, and membrane impermeability severely hinder the efficient delivery of gene drugs. Development of safe and efficient delivery systems remains the key issue to advance gene therapy. Viral vectors and non-viral vectors, the two main delivery systems at present, have their own advantages and disadvantages. Nanomaterial-based non-viral vectors, including polymers, dendrimers, liposomes, lipid nanoparticles, peptides, and inorganic nanoparticles, have the advantages of safety, non-immunogenicity, and ease of massive production and have been extensively explored for gene therapy. To promote their clinical translation, researchers have tried various strategies to improve delivery efficiency and reduce off-target effects. This issue focuses on the latest progress of nucleic acid delivery systems and highlights the challenges for their translation into clinic, aiming to present a fundamental understanding of this field.

Guest Editors

Prof. Dr. Xianrong Qi

Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

Prof. Dr. Ildiko Badea

College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Road, Health Sciences Building, Room 3D01.5, Box 3D01-13, Saskatoon, SK S7N 5E5, Canada

Deadline for manuscript submissions

closed (31 October 2024)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/146096

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

